Why take MIRAPEX?
Why should you take MIRAPEX?
MIRAPEX has shown success in treating RLS patients.
In clinical trials patients taking MIRAPEX for RLS have shown a significant improvement in the frequency and severity of many RLS symptoms. In a clinical trial, 72% of patients on MIRAPEX experienced significant symptom improvements.
MIRAPEX works over the long term.
MIRAPEX offers effective, long-term relief from the symptoms of RLS. In a clinical trial of MIRAPEX, of patients who showed improvement of symptoms in the first 6 months 79% continued to benefit up to 9 months.
Nearly 4 out of 5 patients who responded to MIRAPEX after 6 months’ treatment maintained response at 9 months.
MIRAPEX has an established safety profile.
MIRAPEX is cleared by the kidneys, and MIRAPEX is not expected to have interactions with other drugs metabolized by the liver. Talk to your doctor about what this may mean for your treatment. It is contraindicated for those known to be hypersensitive to it.
In a clinical trial of RLS patients, MIRAPEX was shown to relieve a wide range of RLS symptoms, including:
- Discomfort in arms and legs
- Need to move around
- Sleep disturbance
- Daytime tiredness and sleepiness
- Frequency of symptoms
- Severity of symptoms
- Impact on daily activities
- Mood disturbance
IMPORTANT SAFETY INFORMATION ABOUT MIRAPEX: MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
MIRAPEX may cause you to fall asleep without any warning, even while doing normal daily activities, such as driving. When taking MIRAPEX, hallucinations may occur and sometimes you may feel dizzy, sweaty or nauseated upon standing up. The most common side effects in clinical trials for RLS were nausea, headache, and tiredness. You should talk with your doctor if you experience these problems.
Patients and caregivers should be informed that impulse control disorders/compulsive behaviors may occur while taking medicines, including pramipexole, to treat Parkinson's disease and RLS.
This information is intended for U.S. residents only. Products discussed herein may have different labeling in different countries.
Please see full Prescribing Information, including patient information.
